Share your thoughts with us!

In an era where breakthrough innovations coexist with concerns over drug affordability, Peter Kolchinsky, founder and Managing Partner at healthcare and life sciences investment manager RA Capital, joins us to shed light on the factors and paths forward.

Hercules Capital's Janice Bourque engages with Peter on his No Patient Left Behind initiative, a non-profit dedicated to making medicines affordable for everyone in America.

Topics Include:

  • Overview of the "No Patient Left Behind" movement and its objectives
  • Examining communication challenges within the drug industry
  • The pivotal role of insurance in enabling patient access and affordability
  • Strategies to maintain support for innovation amid pricing concerns
  • Potential solutions to bridge the gap between innovation and affordability


Peter Kolchinsky, PhD is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Peter is an active investor in and board member of publicly- and privately-held companies developing drugs, medical devices, diagnostics, and research tools. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a BA from Cornell University and a PhD in Virology from Harvard University.

This podcast is produced by Hercules Capital, Inc. ("Hercules") for informational purposes only. Views expressed are the speakers' own as of the recording date and do not necessarily reflect those of Hercules or its affiliates. Nothing here is investment, legal, or tax advice, an offer or commitment to provide financing, or an offer of any security. Guests may be associated with current, former, or prospective Hercules portfolio companies. Their appearance is not an endorsement, and they are not compensated.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Hercules Capital. Innehållet i podden är skapat av Hercules Capital och inte av, eller tillsammans med, Poddtoppen.